MedTrace Logo

Comparison of Two SpO2 Targets With Two Different Oximeters - Impact on FiO2 During Nasal High Flow Oxygen Therapy

NCT07168213 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-09

No results posted yet for this study

Summary

Several factors can influence oxygenation monitoring and respiratory support through oxygen therapy: the type of oximeter used, skin pigmentation, and the oxygenation target. It is essential to have an accurate measurement of SpO2 in order to optimize the flow of oxygen or FiO2 administered to patients. The question arises as to the impact of these confounding factors on the FiO2 set during high-flow nasal oxygen therapy. The aim of the study is to evaluate the impact of the oxygenation target and the oximeter used on FiO2 in patients receiving high-flow nasal oxygen therapy.

Conditions

  • Oxygen Delivery
  • Acute Respiratory Failure
  • High Flow Oxygen Therapy
  • Hypoxemic Acute Respiratory Failure

Interventions

DEVICE

Manual FiO2 titration with Philips oximeter (SpO2 target 90%)

FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter

DEVICE

Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)

FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter

DEVICE

Manual FiO2 titration with Philips oximeter (SpO2 target 94%)

FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter

DEVICE

Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)

FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter

Sponsors & Collaborators

  • Laval University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-21
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07168213 on ClinicalTrials.gov